region. The relative proportion of APL cases in comparison with other AML subtypes is higher than that found in northern European and US studies (among non-Hispanics), and is similar to that reported by Central and South American, Spanish and Iranian studies. If confirmed, the peculiar geographical pattern of APL distribution could reflect the spread of susceptible genotypes during ancient migrations from the Middle East and Caspian areas toward the Mediterranean. 16 We believe that our data, together with data from geographically and ethnically heterogeneous cancer registries, are helpful to clarify the role of genetic predisposition in the observed ethnic differences of APL incidence rates.
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor and an established marker of plasma cell differentiation. [1] [2] [3] In diffuse large B-cell lymphomas, MUM1 identifies cases of the non-GCB (germinal center B-cell-like) phenotype and has been linked to poor survival. 4 Expression of MUM1 in multiple myeloma cells and impact on prognosis has not been studied systematically so far. We investigated the predictive value of MUM1 mRNA expression measured by real-time polymerase chain reaction (PCR) in bone marrow samples of well-characterized patients with multiple myeloma. Sixty patients, median age 70 years, were studied. Ten presented with Durie Salmon stage I, 5 had stage II and 45 had stage III. Newly diagnosed patients (N ¼ 48) were treated with different protocols during follow-up. Thirty-six percent were treated with high-dose therapy, 19% were treated with thalidomide-containing regimens, 19% with other regimens (mostly melphalan/prednisone) and 25% received no treatment until now. After a median observation time of 58 months, and median follow-up from bone marrow biopsy of 17 months, 17 patients have died.
Real-time PCR was performed with the ABI Prism 7000 Sequence Detector (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions as described previously.
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MUM1 expression in normal peripheral blood mononuclear cells (PBMNC) was used as a reference (expression level ¼ 1). Additional control samples (PBMNC, N ¼ 5) of healthy donors were tested and had a nearly identical MUM1 expression (range: 0.98-1.39), so that one representative sample was used as endogenous control. High MUM1 expression was found in all myeloma cell lines studied (MM.1S, RPMI-8226 and U266; MUM1 levels were 238.81-, 123.53-and 120.94-fold relative to normal blood, respectively, Table 1 ). MUM1 was clearly detectable in the B-cell line Ramos (10 times lower than in the myeloma cell lines) and, at very low levels in the myeloid cell line K562 and the T-cell line Jurkat. Low expression was also found in bone marrow cells as well as CD19 þ sorted B cells and CD3 þ sorted T cells from a healthy donor and normal splenic tissue (Table 1) .
MUM1 mRNA levels were detected in 60 unsorted bone marrow myeloma samples with a distribution range covering three orders of magnitude (0.34-to 559.38-fold, median: 11.67 relative to normal blood ¼ 1). MUM1 expression levels ranged from lower than in normal PBMNC (two patients) to values higher than in myeloma cell lines. Of note, no significant correlation was observed between the percentage of plasma cells in marrow trephines (CD138 immunohistochemistry) and MUM1 RNA levels (R ¼ 0.16; P ¼ 0.1).
Next, we defined a cutoff value for MUM1 expression, which provided the best degree of discrimination regarding overall survival. Using this cutoff value (o13 vs X13), approximately half of the patients (N ¼ 32) had low and approximately half of the patients (N ¼ 28) had high MUM1 expression. While most of the patients included in the study were newly diagnosed (N ¼ 48), 12 patients had already received treatment. One sample was analyzed after high-dose treatment (MUM1 expression ¼ 1.21), four after induction chemotherapy before high-dose treatment (median MUM1 expression ¼ 4) and seven had progressive disease (median MUM1 expression ¼ 15). Median MUM1 expression in newly diagnosed patient samples (N ¼ 48) was 14. During follow-up, patients received different treatment regimens. Distributions of treatment lines were almost equal in high MUM1 expressers and low MUM1 expressers. Of patients who received therapy during follow-up, 50% with low MUM1 and 47% with high MUM1 were treated with high-dose therapy (no statistical difference). Thalidomide-based regimens were given to 25% of patients with low MUM1 and 26% with high MUM1. Equal number of patients were treated with other regimens (melphalan, prednisone and others) (low MUM1 25% vs high MUM1 26%). However, of patients who received no therapy during follow-up, 67% were found in the low MUM1 group.
To account for the varying myeloma cell fraction in different samples, MUM1 was analyzed in 19 previously untreated myeloma samples after sorting for CD138. Again, a strong but heterogeneous expression was found in the CD 138 þ sorted cell fraction (range: 41-36 611 relative to normal blood, median: 237). Unsorted material was also available in 6 of these 19 samples. The correlation between MUM1 expression levels in sorted and corresponding unsorted patient samples was strong (R ¼ 0.94; P ¼ 0.002), despite a varying percentage of plasma cells in the unsorted samples (30, 5, 10, 70, 35 and 40%, respectively). In bone marrow samples depleted from plasma cells (CD138 À samples) MUM1 expression levels were low (range: 1.3-33.8; median: 1.4, N ¼ 5).
Among the following parametersFSalmon Durie stage, b2-microglobulin, C-reactive protein , white blood count, hemoglobin level, albumin, creatinine, bone marrow plasma cell infiltration, cytogenetic abnormalities (normal cytogenetics vs presence of cytogenetic aberrations, deletion of 13q vs no deletion of 13q, trisomy 11 vs no trisomy 11) and MUM1 mRNA expression testedFcreatinine (P ¼ 0.047), the percentage of plasma cell bone marrow infiltration (P ¼ 0.03), hemoglobin level (P ¼ 0.005), b2-microglobulin (P ¼ 0.004) and MUM1 expression (P ¼ 0.004) were found to be significantly associated with overall survival in univariate analysis (Table 2 ). MUM1 was a strong prognostic marker as a continuous parameter (P ¼ 0.004). When clinical outcome was analyzed in patients with low and high (o13 vs X13) MUM1 expression, median survival was significantly shorter in patients with high MUM1 expression compared to low expressers (45 vs 58 months, Po0.001, hazard ratio 8.43) (Figure 1a ). Survival after 3 years was 82.5% in patients with low MUM1 and 50.4% in patients with high MUM1.
In Cox multivariate analysis, only b2-microglobulin and MUM1 remained independently associated with overall survival (P ¼ 0.00026 and 0.00038, respectively). A combined score of b2-microglobulin and MUM1 expression allowed an even stronger prediction of overall survival (median survival 7 vs 58 months in patients with high MUM1 and high b2-microglobulin (45.5 mg/l; P ¼ 7.58 Â 10
À10
; Figure 1b) . The correlation of 13q deletion to survival did not reach statistical significance in this cohort, although there was a clear trend. Of note, the discriminatory value of MUM1 expression was pronounced in patients without 13q abnormalities (median survival 7 months vs not reached; P ¼ 9.45 Â 10 À5 survival at 12 months, 46.2 vs 100%, Figure 1c) . In contrast, the median survival in patients Letters to the Editor with a 13q deletion was not significantly different between high and low MUM1 expressers (Figure 1d ). Survival analysis and multivariate analysis were also performed after exclusion of pretreated patient samples. In the remaining 48 patients, MUM1 was still a strong prognostic marker as a continuous parameter (P ¼ 0.005). In this analysis, the difference regarding median survival between high MUM1 expressers and low MUM1 expressers was even more pronounced (17 vs 58 months, P ¼ 0.0002, hazard ratio 11.5). MUM1 mRNA remained an unfavorable prognostic marker even after exclusion of the 15 untreated patients (P ¼ 0.0004).
In multivariate analysis, b2-microglobulin and MUM1 remained the only parameters independently associated with overall survival (P ¼ 0.0004 and 0.0005, respectively). A combined score of b2-microglobulin and MUM1 expression as well as the discriminatory value of MUM1 in patients without 13q abnormalities remained highly significant.
Survival analysis also was performed in the 19 sorted, newly diagnosed, patient samples. Again, using a cut off value near the median expression level (200-fold) samples were divided into 10 high and 9 low MUM1 expressers. In this calculation, a clear trend to a worse overall survival in patients having a high MUM1 expression was found. While the median survival was not reached in the 9 patient samples with low MUM1, median survival was only 10 months in patients with a high MUM1 (Figure 2a) . However, owing to low sample number, this difference did not reach statistical significance. Similar to the observation in unsorted patient samples, a combined score of b2-microglobulin and MUM1 expression showed a stronger prediction of overall survival (median survival 4 months vs not reached in patients with high MUM1 (X200) and high b2-microglobulin (45.5 mg/l; N ¼ 4; P ¼ 0.0008, Figure 2b) ).
Fluorescence in situ hybridization (FISH) was performed in 56 patients. Patients without a cytogenetic aberration (N ¼ 8) were predominantly found in low MUM1 expressers. Deletion of 13q seemed to be more frequent (50 vs 32% respectively) in patients with high MUM1 expression, although this association did not reach statistical significance. The median MUM1 expression in samples with a deletion in 13q was 18.7 vs 11.27 without deletion, the median MUM1 expression in samples with a trisomy 11 was 15.2, and the median MUM1 expression in samples with a t(11;14) 10.19, while patients with normal FISH results had a median expression of 7.88.
To validate the data obtained with real-time PCR, we designed conventional reverse transcriptase-PCR (RT-PCR) primers from sequences in exons 4 and 5. We investigated four patient samples with high MUM1 expression (nos. 60, 56, 55 and 59) and four patient samples with a low MUM1 expression (nos. 11, 3, 4 and 12). The myeloma cell line MM.1S, which was used as a positive control, showed a strong MUM1 expression in line with results obtained by real time PCR (not shown). Four patient samples with a high MUM1 expression measured by real time PCR showed a strong MUM1 expression by conventional RT-PCR, while in low MUM1 expressers only a weak band for MUM1 could be amplified (Figure 3 ). Sequence analysis of the PCR product showed 100% homology with MUM1. Additional primer pairs were designed from sequences in exons 2-6 and 8-11, covering the whole length of MUM1 coding region. Again, by conventional RT-PCR using the additional primer pairs, patient samples with a high MUM1 expression showed a stronger MUM1 expression than low MUM1 expressers (not shown). MUM1 protein expression was investigated by western blot analysis in selected patient samples (four with high and four with low MUM1 expression, identical to the patients selected for the RT-PCR assay). In three of four high MUM1 expressers, 
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Figure 1 Letters to the Editor MUM1 protein could be detected, while no protein was found in low MUM1 expressers (Figure 3 ). The myeloma cell line MM.1S (positive control) also showed a strong MUM1 protein expression (not shown).
MUM1 was initially characterized as an oncogene associated with the chromosomal translocation t(6;14) (p25;q32) in multiple myeloma.
1 Interestingly, there are no studies investigating the association of MUM1 with prognosis. Here we show that expression of MUM1 on the mRNA level differs greatly between patients and is strongly related to outcome. High expression of MUM1 was in addition to b2-microglobulin the only myeloma risk factors analyzed in our study that was found to be independently associated with overall survival. A combined score between these two parameters allowed a strong discrimination between high-and low-risk groups. Patients without a deletion of 13q usually present with better survival. 6 In this favorable subgroup, strong expression of MUM1 discriminated between patients with excellent survival from a subgroup of patients with very short life expectancy.
Since real-time PCR may not be suitable for common routine use, we have also investigated MUM1 protein expression. On Western blots the results were consistent with real time as well as conventional PCR. However, using a commonly used antibody, 7 we could only detect subtile differences in immunohistochemical staining of bone marrow biopsies. Intracellular staining of plasma cells may be hampered by unspecific binding to paraprotein. The known weak cytoplasmatic positivity for MUM1 in plasma cells might be owing to such artifacts. However, even when restricting analysis to the varying levels of nuclear staining of MUM1, no association to mRNA expression was found. Sequence analysis of the PCR product did not reveal splice variants or point mutations, which could explain an aberrant immunohistochemical staining behavior. Therefore, this issue remains open for discussion. Our data strongly argue for distinct differences between patients at least on the mRNA level.
The mechanism of MUM1 overexpression is still unclear. We have investigated the possibility of chromosomal changes in region 6p25 by FISH, but could not find alterations in four patients analyzed (the cell line SK-MM-1 carrying t(6;14) was used as positive control). However, mutations or small deletions in regulatory regions of the gene cannot be ruled out.
In conclusion, our data identify MUM1 mRNA expression as an independent risk factor for poor survival in myeloma, particularly in patients without a deletion of 13q. MUM1 therefore should be further evaluated as a novel prognostic marker in patients with multiple myeloma. 
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